Francis Lo, serving as the Chief People Officer for Adaptive Biotechnologies Corp (NASDAQ: ADPT), executed a significant series of stock transactions on June 4, 2026. The filings detail a complex sequence of sales and acquisitions that occurred on the same day, all governed by a pre-established Rule 10b5-1 trading plan that Mr. Lo initiated on September 15, 2025.
The primary transaction involved the disposition of 39,741 shares of Adaptive Biotechnologies common stock. These shares were sold at a price of $17.49 per share, resulting in a total transaction value of $695,070. This sale activity takes place while the company's stock is trading near the $16.71 mark, a level that reflects a market capitalization of approximately $2.68 billion. The stock has experienced a substantial 60% gain over the trailing twelve-month period, a trajectory that has led some analytical assessments to classify the equity as overvalued relative to its calculated fair value.
Simultaneously with the sale, Mr. Lo acquired 19,521 shares of common stock through the exercise of stock options. These acquisitions were executed at varying strike prices ranging from $3.99 to $12.14 per share, culminating in a total value of $172,796. The specific options exercised were drawn from multiple vesting schedules. This included 5,792 shares from a fully vested option, 2,009 shares from an option that began vesting in March 2024, 2,344 shares from an option that began vesting in March 2025, and 9,376 shares from an option that began vesting in March 2026.
Following these transactions, Mr. Lo's direct holding in Adaptive Biotechnologies stands at 250,934 shares. Indirect holdings include an additional 2,500 shares held by his spouse, You Jin Lee. Mr. Lo retains a substantial portfolio of derivative holdings, including 171,823 options with an exercise price of $12.14 expiring in March 2032, 85,065 options at $8.46 expiring in March 2033, 85,953 options at $3.99 expiring in March 2034, and 140,648 options at $8.12 expiring in March 2035.
The timing of these executive transactions coincides with the release of Adaptive Biotechnologies' financial results for the first quarter of 2026. The company reported revenue of $70.9 million, which exceeded analyst expectations by approximately 16.4% against a forecasted $60.89 million. This outperformance was primarily driven by growth within its Minimal Residual Disease (MRD) business segment. While analysts have noted the robust nature of the earnings, no specific upgrades or downgrades were highlighted in the recent reports.
Market data indicates that the stock price for ADPT has shown volatility, with recent closing prices at 16.71 and after-hours trading at 16.50. This volatility is a factor that may influence the execution of insider trading plans, as stock price movements can impact the timing and valuation of transactions under pre-arranged frameworks.